Fasting Study of Hydromorphone Hydrochloride 8 mg Tablets and Dilaudid 8 mg Tablets
Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
The objective of this open-label, randomized, two-period crossover study was to compare the
oral bioavailability of a Mallinckrodt test tablet formulation of hydromorphone 8 mg to an
equivalent oral dose of a commercially available hydromorphone tablet (DILAUDID® 8 mg, Knoll
Pharmaceutical Company) in a test group of healthy subjects under fasting conditions.